title: Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization.
abstract: The effect of patient preimmunization virus sequences on CTL responses during gp160 immunization were studied. Ten HLA-A2+, HIV+ asymptomatic patients with CD4+ T cells >500/mm3 were given two courses of HIV-1 MN rgp160 vaccine over a 2-year period. Envelope epitope-specific CTL responses, using PBMCs, were measured against peptide-coated autologous B lymphoblastoid cell lines. Optimum CTL epitopes were determined by HLA-A2-binding affinity of 9- to 10-mer peptides containing the HLA-A2.1-binding motif. Ten of the high- or intermediate-binding peptides were conserved among >50% of reported clade B HIV strains. These peptide-specific CTL activities and the patient virus sequences in peptide-coding regions were monitored. Six patients showed envelope peptide-specific CTL responses, which correlated with the presence of whole envelope antigen-specific CTL responses. Five of these patients, who showed responses to epitopes in the gp41 region (aa 814-824), had preimmunization virus similar to the vaccine sequence in this region. Three patients who did not show these epitope-specific responses had initially different sequences in the HIV gene encoding that region. The epitope-specific CTL responses appear to reflect recall responses, as only patients infected with virus containing the vaccine sequence developed them and they could be recalled with a second set of vaccine injections. This appears to be reminiscent of the concept of T cell "original antigenic sin." This vaccine was also immunogenic as measured by gp160-specific lymphocyte-proliferative responses. However, increased immune responses did not impact the HIV load or CTL epitope sequences during therapy.
authors.affiliation: Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, USA. kundu@leland.stanford.edu
authors.forename: S K
authors.initials: SK
authors.lastname: Kundu
authors.forename: M
authors.initials: M
authors.lastname: Dupuis
authors.forename: A
authors.initials: A
authors.lastname: Sette
authors.forename: E
authors.initials: E
authors.lastname: Celis
authors.forename: F
authors.initials: F
authors.lastname: Dorner
authors.forename: M
authors.initials: M
authors.lastname: Eibl
authors.forename: T C
authors.initials: TC
authors.lastname: Merigan
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000595:Amino Acid Sequence; D002453:Cell Cycle; D000939:Epitopes / Q000737:chemistry / Q000276:immunology; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology; D006801:Humans; D012367:RNA, Viral / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*; D019562:Viral Load
chemical_list: D016915:AIDS Vaccines; D000939:Epitopes; D012367:RNA, Viral; D014614:Vaccines, Synthetic